Skip to content

effect of tegileridine fumarate injection on postoperative gastrointestinal function in elderly patients undergoing laparoscopic colorectal cancer surgery

Effect of tegileridine fumarate injection on postoperative gastrointestinal function in elderly patients undergoing laparoscopic colorectal cancer surgery

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500105664
Enrollment
Unknown
Registered
2025-07-08
Start date
2025-08-01
Completion date
Unknown
Last updated
2025-07-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Tumor

Interventions

Sufentanil Group ( S):Postoperative Patient-Controlled Intravenous Analgesia (PCIA) with Sufentanil
Tegileridine Fumarate Group (F):Postoperative Patient-Controlled Intravenous Analgesia (PCIA) with Tegileridine Fumarate

Sponsors

The First People’s Hospital of Lianyungang
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patients scheduled to undergo elective laparoscopic colorectal cancer surgery under general anesthesia, with an anticipated operative duration of 1-4 hours; 2. Aged >=65 years, regardless of gender; 3. Body mass index (BMI) 18-30 kg/m²; 4. American Society of Anesthesiologists (ASA) physical status classification of I-III; 5. Intended use of patient-controlled intravenous analgesia (PCIA) postoperatively; 6. Voluntarily participating in the study and providing signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Inability to comprehend the verbal pain rating scale and patient-controlled analgesia (PCA); 2. Known history of allergy to any component of the investigational drug, or hypersensitivity/contraindications to the anesthesia or analgesic agents used in the study; 3. Intellectual disability, language/communication barriers, or psychiatric disorders; 4. Concomitant severe dysfunction of the heart, brain, kidney, lung, or liver, or presence of other malignant tumors; 5. Patients who declined to participate in the study.

Design outcomes

Primary

MeasureTime frame
I-FEED score at POD3;

Secondary

MeasureTime frame
Postoperative complications;Postoperative pain score;First occurrence time of postoperative rescue analgesia, category of medications, dosage;Time of first postoperative flatus?Time of first defecation?Time of first oral feeding;Incidence of delirium;Serum levels of gastrin, vasoactive intestinal peptide (VIP), tumor necrosis factor-a (TNF-a), and intestinal fatty acid-binding protein (I-FABP) at: Baseline (T0) ?POD 1?POD3;Total PCA attempts and successful deliveries within 48 hours postoperatively;Postoperative gastrointestinal function score (I-FEED);Hospitalization costs and length of stay;

Countries

China

Contacts

Public ContactFeng Jiying

The First People’s Hospital of Lianyungang

fengjysd@163.com+86 18961322506

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026